Company
NASDAQ:IMUX
Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.
108 stories · page 6 of 6
The New York-based biotechnology company's promising lead asset vidofludimus calcium (IMU-838) is an oral drug in Phase 3 clinical trials for patients with multiple sclerosis
